IRIS
CEA, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.207
Totale 9.207
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 9.207
Totale 9.207
Salva come PNG Salva come JPEG
Città #
Genova 6.930
Rapallo 1.149
Genoa 1.106
Bordighera 22
Totale 9.207
Salva come PNG Salva come JPEG
Nome #
Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin. 176
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of AKT-mediated gene repression 171
Autophagy in blood cancers: biological role and therapeutic implications. 165
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 164
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 162
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors and DNA repair. 161
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment 158
SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells 153
APO866 activity in hematologic malignancies: a preclinical in vitro study. 143
Ras-induced resistance to lapatinib is overcome by MEK inhibition 140
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival 140
Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. 139
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 139
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience. 137
SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects 132
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. 132
Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis 130
Sirt6 regulates dendritic cell differentiation, maturation, and function 130
Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response 129
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 128
Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells 125
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more. 125
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma 124
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 123
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition 122
Synthesis of Pyrrolidine 3,4-Diol Derivatives with Anticancer Activity on Pancreatic Tumor Cells 121
CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation 121
New insights into biology of chronic myeloid leukemia: implications in therapy. 120
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 116
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 116
Evaluation of prognostic indices in elderly hospitalized patients 116
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 115
Nicotinamide Phosphoribosyltransferase As A Target In Inflammation-Related Disorders. 114
Fasting potentiates the anticancer activity of tyrosin kinase inhibitors by strenghtening MAPK signalling inhibition. 113
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 110
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 107
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 107
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 106
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 106
Synthesis and cancer growth inhibitory activities of 2-fatty-alkylated pyrrolidine-3,4-diol derivatives 104
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 104
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. 102
Intracellular NAD+ depletion induces autophagic-death in Multiple Myeloma cells 102
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications 100
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition 99
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 99
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 99
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 99
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. 98
Biological Insights into Myeloma and Other B Cell Malignancies 98
Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity. 96
Predictive values of two frailty screening tools in older patients with solid cancer: a comparison of SAOP2 and G8 94
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. 93
null 91
Catastrophic NAD+ Depletion through Nampt Inhibition in Activated T Lymphocytes Reduces Demyelination and Disability in EAE. 90
Differentiating diffuse from focal pattern on Computed Tomography in multiple myeloma: Added value of a Radiomics approach 89
Targeting Inflammation in Primary Cardiovascular Prevention 88
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 87
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma 87
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma 84
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. 83
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 83
The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. 83
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 82
Nutrients in the Prevention of Alzheimer's Disease 81
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 78
Abstract CT075: Fasting-mimicking diet and hormone therapy modulates metabolic factors to promote breast cancer regression and reduce side effects 75
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 74
Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma. 73
Synergistic Interaction Between P-glycoprotein Inhibitors and APO866 in Primary Leukemic Cells 71
Radiomics and artificial intelligence analysis of CT data for the identification of prognostic features in multiple myeloma 69
Fasting-mimicking diet and hormone therapy induce breast cancer regression 67
The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells 66
Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model 65
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells 63
null 61
Safety and feasibility of fasting‐mimicking diet and effects on nutritional status and circulating metabolic and inflammatory factors in cancer patients undergoing active treatment 61
SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice 58
Potent Synergistic Activity of the NAD plus Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. 56
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden 55
Depletion of the intracellular coenzyme NAD plus in activated T-cells ameliorates experimental autoimmune encephalomyelitis 53
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 53
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 51
Radiomics and artificial intelligence for outcome prediction in multiple myeloma patients undergoing autologous transplantation: A feasibility study with ct data 49
Chronic myeloid leukemia: Reaching for the cure 48
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 45
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 40
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 40
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 39
Nicotinic acid phosphoribosyltransferase is overexpressed in solid tumors and regulates cancer cell metabolism and susceptibility to FK866 39
The non-coding RNA landscape of plasma cell dyscrasias 37
Resistin, oxidative stress and amyloid beta: a possible link in Alzheimer' disease 36
Fasting-mimicking diet and hormone therapy induce breast cancer regression 36
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent 34
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 33
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial 30
Calciphylaxis in a patient with POEMS syndrome without renal failure and/or hyperparathyroidism. A case report 23
Effect of Geriatric Comanagement in Older Patients Undergoing Surgery for Gastrointestinal Cancer: A Retrospective, Before-and-After Study 21
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial 21
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 21
Totale 9.292
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.551
article - articoli 29.024
book - libri 0
conference - conferenze 527
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.102
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019417 0 0 0 0 0 0 0 0 0 0 213 204
2019/20202.713 125 58 93 288 277 333 379 204 260 353 260 83
2020/20211.050 57 88 112 79 108 68 71 93 88 118 98 70
2021/20221.276 44 65 100 158 64 104 71 254 74 114 64 164
2022/20231.450 148 161 18 148 235 184 10 95 207 32 186 26
2023/2024869 46 97 35 152 99 191 80 104 33 22 10 0
Totale 9.517